ZA932450B - Drugs for the treatment of diabetes - Google Patents

Drugs for the treatment of diabetes

Info

Publication number
ZA932450B
ZA932450B ZA932450A ZA932450A ZA932450B ZA 932450 B ZA932450 B ZA 932450B ZA 932450 A ZA932450 A ZA 932450A ZA 932450 A ZA932450 A ZA 932450A ZA 932450 B ZA932450 B ZA 932450B
Authority
ZA
South Africa
Prior art keywords
diabetes
drugs
treatment
Prior art date
Application number
ZA932450A
Other languages
English (en)
Inventor
Shimon Slavin
Lola Weiss
David Gross
Original Assignee
Kabi Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kabi Pharmacia Ab filed Critical Kabi Pharmacia Ab
Publication of ZA932450B publication Critical patent/ZA932450B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA932450A 1992-04-06 1993-04-05 Drugs for the treatment of diabetes ZA932450B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9201076A SE9201076L (sv) 1992-04-06 1992-04-06 Användningen av gamla läkemedel för behandling av diabetes

Publications (1)

Publication Number Publication Date
ZA932450B true ZA932450B (en) 1993-10-20

Family

ID=20385863

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA932450A ZA932450B (en) 1992-04-06 1993-04-05 Drugs for the treatment of diabetes

Country Status (16)

Country Link
US (1) US5594005A (hu)
EP (1) EP0634931A1 (hu)
JP (1) JPH07506568A (hu)
KR (1) KR950700738A (hu)
CN (1) CN1081671A (hu)
AU (1) AU667362B2 (hu)
CA (1) CA2131831C (hu)
EE (1) EE03090B1 (hu)
HU (1) HUT69710A (hu)
IL (1) IL105285A0 (hu)
NO (1) NO943723D0 (hu)
NZ (1) NZ251494A (hu)
PH (1) PH30820A (hu)
SE (1) SE9201076L (hu)
WO (1) WO1993019756A1 (hu)
ZA (1) ZA932450B (hu)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6133285A (en) * 1998-07-15 2000-10-17 Active Biotech Ab Quinoline derivatives
SE9802549D0 (sv) * 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
SE9802550D0 (sv) * 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
FR2827600A1 (fr) * 2001-07-20 2003-01-24 Lipha Derives acides de quinolone et leurs applications en therapeutique
US8124582B2 (en) * 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
CN102176906B (zh) * 2008-10-09 2014-07-02 新树株式会社 Panduratin衍生物或提琴形凹唇姜提取物的全新用途
MX2013004169A (es) 2010-10-14 2013-06-05 Immunahr Ab 1, 2-dihidro-4-hidroxi-2-oxo-quinolina-3-carboxanilidas como activadores del receptor de hidrocarburo aromatico.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1034124A (en) * 1973-05-11 1978-07-04 Ciba-Geigy Ag Process for the manufacture of new quinolines
FR2340735A1 (fr) * 1976-02-11 1977-09-09 Roussel Uclaf Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament
IE52670B1 (en) * 1981-03-03 1988-01-20 Leo Ab Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
DE3134780A1 (de) * 1981-09-02 1983-03-10 Hoechst Ag, 6000 Frankfurt "sulfonylharnstoffe, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung"
US5310913A (en) * 1989-06-09 1994-05-10 Kabi Pharmacia Aktiebolag Derivatives of quinoline-3-carboxanilide
SE9000624D0 (sv) * 1990-02-22 1990-02-22 Pharmacia Ab New use
SE9001111D0 (sv) * 1990-03-27 1990-03-27 Pharmacia Ab Supportive use

Also Published As

Publication number Publication date
SE9201076L (sv) 1993-10-07
HUT69710A (en) 1995-09-28
CN1081671A (zh) 1994-02-09
EE03090B1 (et) 1998-06-15
NZ251494A (en) 1997-07-27
KR950700738A (ko) 1995-02-20
JPH07506568A (ja) 1995-07-20
US5594005A (en) 1997-01-14
CA2131831C (en) 1999-03-09
NO943723L (no) 1994-10-05
PH30820A (en) 1997-10-17
EP0634931A1 (en) 1995-01-25
AU667362B2 (en) 1996-03-21
AU3913193A (en) 1993-11-08
SE9201076D0 (sv) 1992-04-06
WO1993019756A1 (en) 1993-10-14
CA2131831A1 (en) 1993-10-14
HU9402854D0 (en) 1995-01-30
IL105285A0 (en) 1993-08-18
NO943723D0 (no) 1994-10-05

Similar Documents

Publication Publication Date Title
EP0460912A3 (en) Medicaments for the treatment of sexual disorder
AU7545594A (en) Implantable device for the treatment of aedemas
ZA937483B (en) Process for the preparation of drug pellets
EP0701569A4 (en) IMPROVED METHODS AND REAGENTS FOR DIAGNOSIS AND THERAPY OF DIABETES AND MOERTSCH-WOLTMAN SYNDROME
AU4048295A (en) Peptide medicaments for the treatment of disease
GB9410236D0 (en) Cytotoxic drug therapy
ZA939317B (en) Medicament
AU2806692A (en) Medicament for the treatment of anxiety
EP0592903A3 (en) Use of Ancrod in the manufacture of medications for the treatment of restenosis.
AP9100290A0 (en) Pharmaceutical treatment
ZA932450B (en) Drugs for the treatment of diabetes
GB9103278D0 (en) Drug for the treatment of dermatitis
AU4081393A (en) Medicaments for the treatment of anxiety
GB9217124D0 (en) Medical treatment
IL99666A0 (en) Pharmaceutical compositions for the treatment of diabetes
EG20501A (en) Process for the agrochemical treatment of grasslands
ZA945651B (en) Use of benzenesulphonzlindole derivatives for the preparation of medicines
EP0412938A3 (en) System for the treatment of contactlenses
PH27501A (en) Pharmaceutical formulation and method for the treatment of diabetes mellitus
BG98002U (en) Medicament for the treatment of seborrheic conditions
IL102796A0 (en) Medicinal treatment
ZA925931B (en) Medicinal treatment
GB9211379D0 (en) Pharmaceutical compounds
RO101041B1 (en) Reno-urinary affections treatment medication
GB9204062D0 (en) Medical treatment